Heptares

84 articles with Heptares

• 

  Allergan and Sosei Halt Alzheimer’s Trial Over Safety Concerns

  9/18/2018

  Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
• 

  Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei

  1/19/2018

  Dr. Marshall will leave Sosei at the end of February 2018.

• Sosei Subsidiary, Heptares, Enters Drug R&D Collaboration With Imperial College London Focused on Multiple GPCR Disease Target Opportunities in the Gastro-Intestinal Tract

  1/10/2018

  The strategic multi-year collaboration brings together complementary teams at Heptares and Imperial College London seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target opportunities associated with the GI tract.

• Heptares Scientists Solve Structure of Complement C5a Receptor, an Important Drug Target for Inflammatory and Neurodegenerative Diseases, and Cancer

  1/4/2018

  The findings, published in Nature today, reveal the location of a new allosteric binding site outside the transmembrane helical bundle and provide insights to the mechanisms by which small molecules interact with and modulate the receptor.

• 

  Heptares Founder Shares Her Best Life Sciences Career Advice

  11/22/2017

  Fiona Marshall founded Heptares Therapeutics, which is now one of the leading biotech companies in the UK.

• Heptares Founder Richard Henderson Receives Nobel Prize In Chemistry 2017 For Pioneering Work In Cryo-EM For Visualising Biological Structures

  10/5/2017

• Fidelta Announces An Extension Of Its Drug Discovery Service Agreement With Heptares

  9/6/2017

• Heptares Release: First Subject Dosed In Phase I Clinical Study Of Novel Selective MUSCARINIC M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease

  9/1/2017

• Heptares Enters A New Research And Drug Discovery Collaboration Under Its 'Orbit' Initiative With Juntendo University

  9/1/2017

• Heptares Hosts Scientific Symposium In Celebration Of 10-year Anniversary

  7/13/2017

• Heptares And Peptidream Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Therapeutics In Inflammatory Disease

  6/29/2017

• Heptares Enters a New Research And Drug Discovery Collaboration Under Its "Orbit" Initiative With New York University School Of Medicine

  6/28/2017

• Heptares Plans Relocation To Cambridge, UK

  6/20/2017

• Heptares Solves First Full-Length Structure Of GLP-1 Receptor Bound To Peptide Agonist

  6/1/2017

• Heptares’ Co-Founder And Chief Scientific Officer, Fiona Marshall, Receives 2017 John Daly Lecture Award In Recognition Of Her Outstanding Contribution To GPCR Drug Discovery

  5/18/2017

• Heptares To Receive U.S.$5 Million Milestone Payment From Teva

  5/18/2017

• Heptares Collaboration With AstraZeneca PLC Yields New Insights To Advance Drug Discovery In Pain, Cancer And Inflammation

  4/27/2017

• Sosei Subsidiary Heptares To Receive $12 Million Milestone Payment From AstraZeneca PLC

  4/5/2017

• Heptares Enters Agreement With Daiichi Sankyo To Discover And Develop Novel, Small-Molecules For The Treatment Of Pain

  3/13/2017

• Heptares Enters A New Research Collaboration Under Its 'Orbit' Initiative With The University of Cambridge

  1/31/2017